BNXT (BNXT) News
Follow BNXT (BNXT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
BioNxt advances sublingual everolimus ODF for transplant rejection study
BioNxt Solutions Inc. says it is advancing its proprietary sublingual everolimus oral dissolving film (ODF) for organ transplant rejection, and has initiated a large-animal pharmacokinetic study.
EQUITY | Sep 08, 2026, 07:05 AM UTC
L
BioNxt Advances Cladribine Clinical Program for MS with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Cl
BioNxt Advances Cladribine Clinical Program for MS with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies
EQUITY | Aug 26, 2026, 07:05 AM UTC
L
BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
VANCOUVER, BC / / July 6, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:B
EQUITY | Jul 06, 2026, 07:05 AM UTC
L
BNXT: Closes Private Placement
BioNxt announces closing of non-brokered private placement of units
EQUITY | Jun 23, 2026, 09:20 PM UTC